Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) D Planchard et al.   ANNALS OF ONCOLOGY

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

(2018) Junko Tanizaki et al.   Journal of Thoracic Oncology

Opposing roles of eosinophils in cancer

(2018) Sonja C. S. Simon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies

(2017) Alice Bernard-Tessier et al.   EUROPEAN JOURNAL OF CANCER

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

(2015) Rafael Carretero et al.   NATURE IMMUNOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER